Tech proven31 Mar 2020 14:07
‘Our technology is proven, we’ve been able to reduce that to practice in clinic, which validates the rest of the growing portfolio.’
The reason why the the likes of you know who attack Dan - is because they cannot attack the tech. They cannot attack the fact that their products are wanted because they outperform all other existing drugs in the area of IPF. Drugs that are blockbuster drugs in high need countries.
'We’re about to enter a really exciting phase, which is going to be transformational for the company, completing transactions and moving assets forward.'
They belittle the conversation and turn it onto them. Read their posts and just look at the amount of times they use 'I' or 'I'm', anyone would think this board was about him. Their egos are out of control. Bless. When the reality is, Nuformix have great assets and are in the process of moving these forward.
‘We are very comfortable right now with the small raise we did before Christmas, and ongoing income we have with Ebers activities allows us to progress both NXP002 and NXP004 programmes without delay or reliance on third parties’
Fantastic. Low outgoings and no reliance on third parties. The hysterical posters (you know who they are) know absolutely nothing, but they sure spout like they do. Pathetic at best.
‘To be able to bring him (Karl Keegan) onto the team at this time is absolutely perfect for us. He’s got an excellent track record in delivering value across a range of capital markets life science companies and we’re really looking forward to rolling our sleeves up with him as we go forward over the next couple of months’.
Yes, so as they (you know who they are), waffle about themselves and how hurt they are by insults, whilst degrading the conversation, the company is getting their sleeves rolled up and turning Nurformix into the next phase.
As far as I am concerned, I am more than happy to be invested in this company and wish it to do well for both my money and for patients that will benefit form the great tech.
Sign In
Follow the stocks
